Effects of naproxen, diclofenac and piroxicam on Mandibular joint pai
Phase 3
- Conditions
- Temporo Mandibular Disorders.Temporomandibular joint disordersM26.6
- Registration Number
- IRCT20210807052101N1
- Lead Sponsor
- Rafsanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
Pain in masticatory muscles
Limitation in mouth opening
Clicking sound
TMJ touch sensivity
No systemic disease
No previous supportive treatments
Exclusion Criteria
Existence of systemic disease
Receive previous supportive treatments
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie NSAID efficacy in temporomandibular joint disorders (TMD) like IRCT20210807052101N1?
How do naproxen, diclofenac, and piroxicam compare to standard-of-care NSAIDs for TMD pain management in phase III trials?
Which biomarkers predict response to COX-1/COX-2 inhibition in TMD patients treated with naproxen, diclofenac, or piroxicam?
What are the safety profiles of naproxen, diclofenac, and piroxicam in phase III TMD trials sponsored by Rafsanjan University of Medical Sciences?
Are there combination therapies involving naproxen, diclofenac, or piroxicam for M26.6 temporomandibular joint disorders with improved outcomes?